On Monday, U.S. District Judge Brian Murphy issued a long-anticipated decision, pausing recent efforts from HHS Secretary Robert F. Kennedy Jr. to overhaul U.S. vaccine policy.

In his opinion, Judge Murphy said that Secretary Kennedy and the CDC acted unlawfully in appointing 13 new members to the Advisory Committee on Immunization Practices last year and revising the federal vaccine schedule in January.

The injunction stayed the appointments of the new ACIP members – many of whom Murphy found did not have “any relevant vaccine-related experience or expertise” – and voided any actions the committee took since their appointment. The temporary ruling also effectively cancelled this week’s planned ACIP meeting in which COVID-19 vaccines were to be discussed.

However, the decision has potentially created some unintended consequences – such as jeopardizing children’s access to free RSV vaccines – related to decisions the now-stayed ACIP panel previously made.

While many are championing the ruling as a win for evidence-based public health amid a landscape of eroding vaccine confidence and resurgent infectious disease outbreaks, others question how long this temporary ruling can hold if the government appeals to higher courts. The White House is reportedly carefully weighing its next move in the case given the political risks ahead of the 2026 midterm elections.

One thing is certain: We’ll be watching this space to see what comes next.

– Rachel Bridges, Senior Director

The conflict in the Middle East is pressuring pharma’s supply chains, through the developments have exposed distinct vulnerabilities for branded medicines and generics.

For branded drugmakers, the immediate concern is logistics. Airspace disruptions and the shutdown of major Gulf cargo hubs, including Dubai, Abu Dhabi and Doha, are forcing companies to reroute shipments of oncology drugs and other temperature-sensitive medicines. That creates acute risk for biologics, specialty products and clinical trial materials that depend on strict cold-chain handling and narrow delivery windows. In these categories, delays are not just a cost issue; it can threaten product viability and patient access. Trade groups in the UK are now warning that if the conflict persists, medicine supply risks could broaden. 

Generics, by contrast, face a more structural economic threat. The sector is dependent on India-centered manufacturing as well as oil and petrochemical inputs that move through or are priced off the Gulf. If the Strait of Hormuz remains disrupted or energy prices stay elevated, generic manufacturers could be squeezed by rising input, packaging and freight costs – given thin margins and reduced ability to absorb sustained cost inflation.

For now, companies are relying on rerouting, shipment triage and inventory buffers. But if the conflict deepens, branded products may see the sharper short-term cold-chain disruption, while generics could face the more durable margin and supply shock.

– Leslie Isenegger, Head, Client Development, RC Resolve

The launch of TrumpRx has been positioned as a breakthrough in lowering U.S. drug prices, specifically hailed as “one of the most transformative health care initiatives of all time.”

The platform continues to expand as additional therapies are added – most recently from Amgen and GSK – prompting broader discussion about its real-world impact. Two voices shaping that conversation: entrepreneur and TV personality Mark Cuban and HHS multi-hyphenate Chris Klomp.

Cuban has acknowledged the platform is “saving people a lot of money” on certain drugs, particularly in areas such as IVF, calling those savings “a lifesaver” for some patients. His support is also philosophical, rooted in long-standing advocacy for transparent, net pricing and reducing reliance on intermediaries such as PBMs.

But even Cuban – and now Klomp – are clear: This isn’t a full solution.

As Klomp noted onstage at STAT’s Breakthrough Summit East, “The goal was not actually some massive reach,” adding that “170 million Americans are commercially insured, 68 million Americans are on Medicare, the balance are on Medicaid and CHIP largely. TrumpRx is not for most of them; it’s cash pay.”

This highlights a fundamental disconnect: Lower prices do not automatically translate to better access.

TrumpRx creates a perception of progress that doesn’t fully align with the patient experience. Because in drug pricing, availability is not the same as access or affordability.

And progress, while real, is not the same as transformation.

– Leah Nebbia, Senior Group Director

• March 27-30 – Annual Meeting & Exposition, American Pharmacists Association

• “Makary claims the plan was always for Prasad to exit the FDA after a year, but Prasad said just the day before that he would continue to serve as long as he was needed. If his departure next month was always Makary’s plan, did anyone bother to tell Prasad?” – Heather McKenzie, BioSpace
• “The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully reform the system…We need to reform the root of the convoluted system we have for paying for prescription drugs in outpatient clinics.” – Sujith Ramachandran, STAT
• “It’s immoral to condemn people to die from a once-fatal infectious disease that medicine has made treatable. Not many problems can be solved by simply taking a daily pill. HIV infection is one of them, and we can’t afford to go back to the time when it wasn’t.” – Maia Szalavitz, The New York Times

• A SXSW panel, moderated by RC Resolve’s Leslie Isenegger, discussed how the FDA is rapidly expanding AI use as it tries to regain footing after DOGE-era disruption, noting that 70% of staff now have access to “Elsa,” a generative AI tool. MedCity News: Which FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?
• The White House has reportedly tightened its control over HHS agency messaging and operations after a wave of MAHA-related setbacks, even as Secretary Kennedy remains in Trump’s good graces. The Wall Street Journal: White House Puts RFK Jr.’s HHS on Tighter Leash After MAHA Setbacks.
• Legal experts suggest biopharma companies are quietly exploring licensing-contract changes – including delaying overseas launches or rewriting royalty terms – to blunt the impact of MFN pricing in the U.S., though reps of Roche and Eli Lilly deny any impact in such areas. Endpoints: Drugmakers consider licensing deal tweaks to soften MFN impact.
• A federal appeals court revived a lawsuit accusing AbbVie, AstraZeneca, Novartis and Sanofi of inflating 340B drug prices, reopening claims after a district judge dismissed the case in 2024. Endpoints: Four major drugmakers will face revived case over 340B prices.
• Trump is getting more credit than former President Biden for actions to lower drug prices, according to a new KFF poll – though responses were sharply divided across party lines. STAT: Trump is getting more credit than Biden for efforts to lower drug prices.
• Rare-disease advocates staged a symbolic funeral at the FDA to demand faster, more flexible approvals for MPS therapies, while HHS countered that the agency must have clear evidence of clinical benefit instead of “rubber-stamped” treatments. Fierce Pharma: Rare disease advocates stage ‘funeral’ at FDA, demand 4 actions of agency and Congress.
• An Axios-Ipsos poll found cost is not the main reason Americans are avoiding GLP-1 weight-loss drugs, as only 16% of uninterested nonusers cited expense as a primary reason. Axios: Axios-Ipsos poll: Cost isn’t discouraging GLP-1 use.
• French healthcare professionals are warning that unstable pricing policy, weak manufacturing attractiveness and slow access to innovation are undermining medicine availability in France. Pink Sheet: French Health Care Professionals Warn Of Medicine Access Problems.
• House lawmakers, during a Wednesday hearing, agreed that provider consolidation is a main driver of healthcare costs, though Democrats argued those reforms are secondary to the affordability and access damage they say would come from Medicaid cuts passed in 2025. Fierce Healthcare: To tackle healthcare costs, representatives weigh curbs on provider consolidation.